Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 18, 2024 - Issue
Submit an article Journal homepage
168
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS

Pan Lei1 Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China;2 Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, People’s Republic of ChinaView further author information
,
Wanying Shen2 Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, People’s Republic of ChinaView further author information
,
Huijuan Tang2 Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, People’s Republic of ChinaView further author information
,
Li You2 Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, People’s Republic of ChinaView further author information
,
Guoyi Chen2 Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, People’s Republic of ChinaView further author information
,
Yijun Tang1 Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Wei Lu3 Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1-12 | Received 26 Aug 2023, Accepted 21 Dec 2023, Published online: 04 Jan 2024

References

  • Abankwa D, Gorfe AA, Inder K, Hancock JF. Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci USA. 2010;107(3):1130–1135. doi:10.1073/pnas.0903907107
  • Thein KZ, Biter AB, Hong DS. Therapeutics targeting mutant KRAS. Annu Rev Med. 2021;72(1):349–364. doi:10.1146/annurev-med-080819-033145
  • Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17–33. doi:10.1016/j.cell.2017.06.009
  • Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467. doi:10.1158/0008-5472.CAN-11-2612
  • Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101–1110. doi:10.1016/j.annonc.2021.06.001
  • Cx Z, Xq G, Xn Z, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159. doi:10.1186/s12943-022-01629-2
  • Sf B, Mh U, Nagasaka M, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021;40(3):819–835. doi:10.1007/s10555-021-09990-2
  • Tang DL, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer. 2021;20(1):128. doi:10.1186/s12943-021-01422-7
  • Qian YZ, Gong YT, Fan ZY, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1):130. doi:10.1186/s13045-020-00958-3
  • Mao ZW, Xiao HY, Shen PP, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022;8(1):5. doi:10.1038/s41421-021-00368-w
  • Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223. doi:10.1038/s41586-019-1694-1
  • Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71. doi:10.1158/2159-8290.CD-19-1167
  • Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120–131. doi:10.1056/NEJMoa2204619
  • Du P, Xuan LL, An Z, Zhang YH. Development and validation of a robust and sensitive HPLC-MS/MS method for the quantitation of MRTX849 in plasma and its application in pharmacokinetics. Analyst. 2022;147(6):1175–1180. doi:10.1039/d1an01928g
  • Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem. 2020;63(13):6679–6693. doi:10.1021/acs
  • FDA. Bioanalytical method validation guidance for industry. USA; 2018. Available from: https://www.fda.gov/media/70858/download. Accessed February 1, 2023.
  • Chinese Pharmacopoeia Commission. Guidelines for validation of methods for quantitative analysis of biological samples, Chinese pharmacopoeia volume IV, China, Beijing; 2020. 466–472.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.